At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 902 enrolled
Drug / intervention
AL-4943A ophthalmic solution +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3, Efficacy and Safety Study of AL-4943A Ophthalmic Solution, 0.77% in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model
In Brief
A Phase 3 clinical trial evaluating AL-4943A ophthalmic solution, Olopatadine hydrochloride ophthalmic solution, 0.2%, and 2 other interventions for Allergic Conjunctivitis. Completed, enrolled 902 participants.
Detailed Summary
The purpose of this study is to evaluate an ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge (CAC) model.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 2012
Enrollment StartJan 2013
Primary CompletionJul 2013
TodayJul 2026
First PostedDec 6, 2012
Enrollment StartJan 1, 2013
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 13.6 years ago
Interventions
AL-4943A ophthalmic solutiondrug
Olopatadine hydrochloride ophthalmic solution, 0.2%drug
Olopatadine hydrochloride ophthalmic solution, 0.1%drug
AL-4943A ophthalmic solution vehicledrug